Overview

Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)

Status:
Completed
Trial end date:
1998-07-08
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to determine the efficacy of etanercept in children with polyarticular course JRA.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Etanercept